Ligand to Report Second Quarter Financial Results on August 8

Rhea-AI Summary

Ligand Pharmaceuticals (NASDAQ: LGND) will announce its second quarter 2022 financial results on August 8, 2022, following the U.S. market close. A conference call led by CEO John Higgins, President and COO Matt Foehr, and CFO Matt Korenberg will commence at 4:30 p.m. ET. Investors can participate via a dial-in or by accessing the live webcast. Ligand continues to focus on developing technologies that aid in drug discovery for the biopharmaceutical industry, maintaining a diversified revenue stream through strategic partnerships with major pharmaceutical companies.

Positive

• Diversified revenue streams from partnerships with major pharmaceutical companies.
• Focus on low-cost structure while engaging in drug discovery and development.

Negative

• None.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg.

Conference Call and Webcast Information

What:	Ligand conference call to discuss financial results and provide general business updates
Date:	Monday, August 8, 2022
Time:	4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Conference Call:	Dial (866) 374-5140 within the U.S.
	Dial (808) 238-9813 outside the U.S.
	Conference PIN is 84255874#
Webcast:	Live and replay webcast of the call are available here.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) ultimately to generate our revenue. Ligand’s OmniAb^® technology platform is a patent-protected transgenic animal platform used in the discovery of fully human monoclonal and bispecific therapeutic antibodies. The Captisol^® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology^® is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.

Follow Ligand on Twitter @Ligand_LGND.

We use Twitter and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our Twitter account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220722005458/en/

Ligand Pharmaceuticals Incorporated

Simon Latimer

investors@ligand.com

(858) 550-7766

Twitter: @Ligand_LGND

LHA Investor Relations

Bruce Voss

bvoss@lhai.com

(310) 691-7100

Source: Ligand Pharmaceuticals Incorporated

FAQ

When will Ligand Pharmaceuticals report its Q2 2022 financial results?

Ligand Pharmaceuticals will report its Q2 2022 financial results on August 8, 2022.

Who will speak on Ligand Pharmaceuticals' conference call for Q2 2022 results?

The conference call will feature CEO John Higgins, President and COO Matt Foehr, and CFO Matt Korenberg.

What time is the Ligand Pharmaceuticals conference call on August 8, 2022?

The conference call will begin at 4:30 p.m. ET.

How can I access the Ligand Pharmaceuticals conference call?

You can access the conference call by dialing (866) 374-5140 within the U.S. or (808) 238-9813 internationally, or by visiting their investor relations website for the live webcast.

What is the business focus of Ligand Pharmaceuticals?

Ligand Pharmaceuticals focuses on developing and acquiring technologies that assist in drug discovery and development for the biopharmaceutical industry.